Oppenheimer on Jasper (JSPR): 'adding cohorts and remains on track to begin a registrational program in CSU with a Ph2b study expected to initiate in 2H25'
Tweet Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $80.00 price target on Jasper Therapeutics (NASDAQ: JSPR)The analyst comments "JSPR ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
